BrainStorm Cell Therapeutics Inc. Signs MOU for Collaboration with Massachusetts General Hospital and University of Massachusetts Medical School to Conduct Human Clinical Trials in the United States

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (BCLI.OB), a developer of adult stem cell technologies and CNS therapeutics, announced today that it has entered into a Memorandum of Understating with Massachusetts General Hospital and the University of Massachusetts Medical School in anticipation of applying for FDA approval to begin ALS human clinical trials in the United States.